Document is current
Any future updates will be listed below
-
Authors
Ghiani, M. https://orcid.org/0000-0002-5827-6822
Naessens, D.
Takacs, P.
Myers, D.
Bokemeyer, B.
Wilke, T.
-
Funding
Funding for this research was provided by:
Janssen Pharmaceutica, NV, Beerse, Belgium. (NA)
- License Information
-
More Information
Article History
Accepted: 31 January 2021
First Online: 10 February 2021
Declarations
:
: Because the present study was non-interventional, had a retrospective design, and was based on anonymized data, informed consent of patients was not required. This is in accordance with German law and policies of the institutions assessing patient-level data (IPAM, and AOK PLUS). The study was evaluated by a scientific steering committee to which all the authors belonged and was based on a study protocol approved before start of data analysis.
: Marco Ghiani participated in this study as a staff member of IPAM; the work of IPAM in this study was financed by Janssen Pharmaceutica. Dominik Naessens, Peter Takacs, and David Myers are employees of Janssen. Ulf Maywald is an employee of AOK PLUS and reports Honoria from Roche and MSD. Thomas Wilke and Bernd Bokemeyer have received honoraria from several pharmaceutical companies, e.g., Novo Nordisk, Abbvie, Merck, GSK, Astra Zeneca, Bayer, Boehringer Ingelheim, and Pharmerit
